金陵药业股份有限公司 2025 年 1-6 月非经营性资金占用及其他关联资金往来情况汇总表 单位：人民币万元 非经营性 资金占用 资金占用方名称 占用方与上 市公司的关 联关系 上市公司核算的会计科目 2025 年期初占 用资金余额 2025 年度 1-6 月占用累计发 生金额（不含 利息） 2025 年度 1- 6 月占用资 金的利息 （如有） 2025 年度 1-6 月偿还累计发 生金额 2025 年度 6 月末占用资金 余额 占用 形成 原因 占用性质 控股股 东、实际 控制人及 其附属企 业 - - - - - 小计 - - - - - 前控股股 东、实际 控制人及 其附属企 业 - - - - - 小计 - - - - - 其他关联 方及其附 属企业 - - - - - 小计 - - - - - 总计 - - - - - 其他关联 资金往来 资金往来方名称 往来方与上 市公司的关 联关系 上市公司核算的会计科目 2025 年期初占 用资金余额 2025 年度 1-6 月占用累计发 生金额（不含 利息） 2025 年度 1- 6 月占用资 金的利息 （如有） 2025 年度 1-6 月偿还累计发 生金 ...

证券代码：000919 证券简称：金陵药业 公告编号：2025-063 金陵药业股份有限公司 关于同一控制下企业合并追溯调整财务数据的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 金陵药业股份有限公司（以下简称"公司"）于2025年8月26日 召开第九届董事会第二十次会议，审议通过了《关于同一控制下企 业合并追溯调整财务数据的议案》。具体情况如下： 一、同一控制下企业合并的基本情况及追溯调整财务报表数据 的原因 2024年10月18日，公司与南京新工投资集团有限责任公司（以 下简称"新工集团"）、南京新工新兴产业投资管理有限公司（以 下简称"新工新兴"）、南京紫金资产管理有限公司（以下简称" 紫金资管"）签署《基金份额转让协议》，以现金方式受让新工集 团持有的南京新工医疗产业投资基金合伙企业（有限合伙）（以下 简称"基金"）28.46%出资份额和紫金资管持有的基金16.67%出资 份额。公司原持有33.33%的基金份额，上述基金份额转让完成后， 公司合计持有基金78.46%的份额。后续公司与新工集团、新工新兴 将基金持有的南京梅山医院有限责任公司（以下 ...

金陵药业股份有限公司监事会 三、关于2025年半年度募集资金存放与使用情况的专项报告的 审核意见 经审议，监事会认为：公司2025年半年度募集资金的存放与使 用符合《上市公司募集资金监管规则》和《主板上市公司规范运作》 等相关规定，不存在违规存放和使用募集资金的情况。 <以下无正文> （此页无正文，为金陵药业股份有限公司监事会关于第九届监 事会第十九次会议相关事项的审核意见签字页） 关于第九届监事会第十九次会议相关事项的审核意见 根据《中华人民共和国公司法》《深圳证券交易所股票上市规 则》《深圳证券交易所上市公司自律监管指引第1号——主板上市公 司规范运作》（以下简称"《主板上市公司规范运作》"）等有关 法律法规、规范性文件及《公司章程》的规定，金陵药业股份有限 公司（以下简称"公司"）监事会对公司第九届监事会第十九次会 议审议的相关事项进行了认真审核，发表审核意见如下： 一、关于同一控制下企业合并追溯调整财务数据的审核意见 经审议，监事会认为：公司本次追溯调整事项符合《企业会计 准则》等的相关规定，追溯调整后的财务报表能够客观、公允地反 映公司的财务状况和经营成果。本次追溯调整事项的决策程序符合 有关法律、 ...

一、监事会会议召开情况 1、金陵药业股份有限公司（以下简称"公司"）第九届监事会第 十九次会议通知于 2025 年 8 月 15 日以专人送达、邮寄、电子邮件等 方式发出。 2、本次会议于 2025 年 8 月 26 日以现场会议和通讯会议相结合 的方式召开。 证券代码：000919 证券简称：金陵药业 公告编号：2025-060 金陵药业股份有限公司 第九届监事会第十九次会议决议公告 公司及监事会全体成员保证信息披露内容的真实、准确和完整， 没有虚假记载、误导性陈述或重大遗漏。 3、会议应出席监事 5 名，实际出席监事 5 名（其中：出席现场 会议的 2 人，参加通讯会议的 3 人，廖光友、陈晓灵、牛磊以通讯表 决方式出席会议）。 4、会议由监事会主席周宇生主持，公司董事会秘书列席了会议。 5、本次监事会会议的召开符合有关法律、行政法规、部门规章、 规范性文件和《公司章程》的规定。 二、监事会会议审议情况 1、审议通过了《关于同一控制下企业合并追溯调整财务数据的 议案》。 表决结果：5 票同意，0 票反对，0 票弃权。 具体内容详见 2025 年 8 月 28 日《中国证券报》《证券时报》《上 海证券报》及 ...

证券代码：000919 证券简称：金陵药业 公告编号：2025-060 金陵药业股份有限公司 第九届监事会第十九次会议决议公告 公司及监事会全体成员保证信息披露内容的真实、准确和完整， 没有虚假记载、误导性陈述或重大遗漏。 一、监事会会议召开情况 1、金陵药业股份有限公司（以下简称"公司"）第九届监事会第 十九次会议通知于 2025 年 8 月 15 日以专人送达、邮寄、电子邮件等 方式发出。 2、本次会议于 2025 年 8 月 26 日以现场会议和通讯会议相结合 的方式召开。 3、会议应出席监事 5 名，实际出席监事 5 名（其中：出席现场 会议的 2 人，参加通讯会议的 3 人，廖光友、陈晓灵、牛磊以通讯表 决方式出席会议）。 4、会议由监事会主席周宇生主持，公司董事会秘书列席了会议。 5、本次监事会会议的召开符合有关法律、行政法规、部门规章、 规范性文件和《公司章程》的规定。 二、监事会会议审议情况 1、审议通过了《关于同一控制下企业合并追溯调整财务数据的 议案》。 表决结果：5 票同意，0 票反对，0 票弃权。 具体内容详见 2025 年 8 月 28 日《中国证券报》《证券时报》《上 海证券报》及 ...

证券代码：000919 证券简称：金陵药业 公告编号：2025-059 5、本次董事会会议的召开符合有关法律、行政法规、部门规章、 规范性文件和《公司章程》的规定。 金陵药业股份有限公司 第九届董事会第二十次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 1、金陵药业股份有限公司（以下简称"公司"）第九届董事会 第二十次会议通知于 2025 年 8 月 15 日以专人送达、邮寄、电子邮件 等方式发出。 2、本次会议于 2025 年 8 月 26 日以现场会议和通讯会议相结合 的方式召开。 3、会议应出席董事 9 名，实际出席董事 9 名（其中：出席现场 会议的 7 人，参加通讯会议的 2 人，邹勇志、高燕萍以通讯表决方式 出席会议）。 4、本次会议由公司董事长陈胜先生主持，公司 2 名监事和部分 高级管理人员列席了会议。 二、董事会会议审议情况 1、审议通过了《关于增补公司第九届董事会提名委员会委员的 议案》。 同意增补邹勇志为公司第九届董事会提名委员会委员，任期自本 次董事会会议通过之日起至本届董事会任期届满时止。增补后 ...

2、本次会议于 2025 年 8 月 26 日以现场会议和通讯会议相结合 的方式召开。 证券代码：000919 证券简称：金陵药业 公告编号：2025-059 金陵药业股份有限公司 第九届董事会第二十次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 1、金陵药业股份有限公司（以下简称"公司"）第九届董事会 第二十次会议通知于 2025 年 8 月 15 日以专人送达、邮寄、电子邮件 等方式发出。 3、会议应出席董事 9 名，实际出席董事 9 名（其中：出席现场 会议的 7 人，参加通讯会议的 2 人，邹勇志、高燕萍以通讯表决方式 出席会议）。 4、本次会议由公司董事长陈胜先生主持，公司 2 名监事和部分 高级管理人员列席了会议。 5、本次董事会会议的召开符合有关法律、行政法规、部门规章、 规范性文件和《公司章程》的规定。 二、董事会会议审议情况 1、审议通过了《关于增补公司第九届董事会提名委员会委员的 议案》。 同意增补邹勇志为公司第九届董事会提名委员会委员，任期自本 次董事会会议通过之日起至本届董事会任期届满时止。增补后 ...

[Part I Important Notice, Table of Contents, and Definitions](index=2&type=section&id=Part%20I%20Important%20Notice%2C%20Table%20of%20Contents%2C%20and%20Definitions) This section provides crucial disclaimers, the report's structured table of contents, and definitions of key terms for clarity [Important Notice](index=2&type=section&id=Important%20Notice) Company's board, supervisory board, and senior management guarantee the truthfulness, accuracy, and completeness of the semi-annual report, assuming legal responsibility - The company's board of directors, supervisory board, and senior management guarantee the truthfulness, accuracy, and completeness of the semi-annual report content, assuming legal responsibility[3](index=3&type=chunk) - Company's principal Chen Sheng, chief financial officer Wang Yang, and head of accounting department Chang Ting declare that the financial report in this semi-annual report is true, accurate, and complete[3](index=3&type=chunk) - The company plans not to distribute cash dividends, bonus shares, or convert capital reserves into share capital for the half-year period[4](index=4&type=chunk) [Table of Contents](index=3&type=section&id=Table%20of%20Contents) This section lists the report's structured directory, covering company profile, financial indicators, management discussion, corporate governance, and financial statements - The report's table of contents is clear, covering core content such as company profile, financial indicators, management discussion, corporate governance, significant matters, share changes, bond information, and financial reports[6](index=6&type=chunk) [Definitions](index=5&type=section&id=Definitions) This section defines common terms used in the report, including legal regulations, government agencies, company entities, industry terms, and currency units - The reporting period refers to January 1, 2025, to June 30, 2025[10](index=10&type=chunk) - Jinling Pharmaceutical Co., Ltd. (referred to as "the Company/Jinling Pharmaceutical") primarily operates in two segments: pharmaceutical and medical device manufacturing, and medical and eldercare services[10](index=10&type=chunk)[25](index=25&type=chunk) - Important industry terms such as GMP (Good Manufacturing Practice for Pharmaceuticals), DRGs (Diagnosis-Related Groups), "Two-Invoice System," and consistency evaluation are clearly defined[11](index=11&type=chunk) [Part II Company Profile and Key Financial Indicators](index=7&type=section&id=Part%20II%20Company%20Profile%20and%20Key%20Financial%20Indicators) This section provides an overview of the company's basic information, contact details, and key financial performance metrics and indicators [1. Company Profile](index=7&type=section&id=1.%20Company%20Profile) Jinling Pharmaceutical Co., Ltd., stock code 000919, is listed on the Shenzhen Stock Exchange, with Chen Sheng as its legal representative - Stock Abbreviation: Jinling Pharmaceutical, Stock Code: **000919**[13](index=13&type=chunk) - Stock Exchange where listed: Shenzhen Stock Exchange[13](index=13&type=chunk) - Company's Legal Representative: Chen Sheng[13](index=13&type=chunk) [2. Contact Person and Contact Information](index=7&type=section&id=2.%20Contact%20Person%20and%20Contact%20Information) The company's board secretary is Wang Yang, with Zishu Nai and Minyi Yang as securities affairs representatives, all located at Jinling Pharmaceutical Building, Nanjing - Board Secretary: Wang Yang; Securities Affairs Representatives: Zishu Nai, Minyi Yang[14](index=14&type=chunk) - Contact Address: Jinling Pharmaceutical Building, No. 238 Zhongyang Road, Nanjing[14](index=14&type=chunk) [3. Other Information](index=7&type=section&id=3.%20Other%20Information) No changes occurred in the company's contact information, information disclosure, or document storage locations during the reporting period - The company's registered address, office address, website, and email address remained unchanged during the reporting period[15](index=15&type=chunk) - Information disclosure and document storage locations remained unchanged during the reporting period[16](index=16&type=chunk) [4. Key Accounting Data and Financial Indicators](index=8&type=section&id=4.%20Key%20Accounting%20Data%20and%20Financial%20Indicators) The company's operating revenue and net profit both decreased year-on-year, with revenue down **6.62%** and net profit attributable to shareholders down **14.08%** - The company retrospectively adjusted or restated prior-year accounting data due to business combinations under common control[18](index=18&type=chunk) Key Accounting Data and Financial Indicators (Year-on-Year Change) | Indicator | Current Period (RMB) | Prior Period Adjusted (RMB) | YoY Change | | :--- | :--- | :--- | :--- | | Operating Revenue | 1,601,071,008.21 | 1,714,541,843.46 | -6.62% | | Net Profit Attributable to Shareholders of Listed Company | 48,333,532.45 | 56,255,420.62 | -14.08% | | Net Profit Attributable to Shareholders of Listed Company (Excluding Non-Recurring Gains/Losses) | 35,510,166.16 | 45,262,925.14 | -21.55% | | Net Cash Flow from Operating Activities | 15,844,298.86 | 21,359,985.63 | -25.82% | | Basic Earnings Per Share (RMB/share) | 0.0777 | 0.0991 | -21.59% | | Diluted Earnings Per Share (RMB/share) | 0.0777 | 0.0991 | -21.59% | | Weighted Average Return on Net Assets | 1.27% | 1.72% | -0.45% | | Total Assets (Period-End) | 6,054,547,027.24 | 6,088,855,025.59 | -0.56% | | Net Assets Attributable to Shareholders of Listed Company (Period-End) | 3,772,432,638.51 | 3,791,090,837.42 | -0.49% | [5. Differences in Accounting Data Under Domestic and Overseas Accounting Standards](index=8&type=section&id=5.%20Differences%20in%20Accounting%20Data%20Under%20Domestic%20and%20Overseas%20Accounting%20Standards) The company reported no differences in net profit and net assets between international/overseas accounting standards and Chinese accounting standards - The company reported no differences in net profit and net assets between financial reports disclosed under International Accounting Standards and Chinese Accounting Standards during the reporting period[19](index=19&type=chunk) - The company reported no differences in net profit and net assets between financial reports disclosed under overseas accounting standards and Chinese Accounting Standards during the reporting period[20](index=20&type=chunk) [6. Non-Recurring Gains and Losses Items and Amounts](index=8&type=section&id=6.%20Non-Recurring%20Gains%20and%20Losses%20Items%20and%20Amounts) The company's total non-recurring gains and losses for the period amounted to **RMB 12.82 million**, primarily from fair value changes, entrusted investments, and government subsidies Non-Recurring Gains and Losses Items and Amounts | Item | Amount (RMB) | Explanation | | :--- | :--- | :--- | | Gains/Losses on Disposal of Non-Current Assets | -44,966.62 | | | Government Subsidies Recognized in Current Period P&L | 3,425,735.47 | | | Gains/Losses from Changes in Fair Value | 12,013,263.09 | | | Gains/Losses from Entrusted Investments or Asset Management | 5,672,695.26 | Wealth management product income | | Other Non-Operating Income and Expenses | 498,700.87 | | | Less: Income Tax Impact | 4,807,436.14 | | | Minority Interest Impact (After Tax) | 3,934,625.64 | | | Total | 12,823,366.29 | | - The company has not classified any non-recurring gains and losses items as recurring gains and losses items[23](index=23&type=chunk) [Part III Management Discussion and Analysis](index=10&type=section&id=Part%20III%20Management%20Discussion%20and%20Analysis) This section provides a comprehensive analysis of the company's business operations, financial performance, core competencies, and risk factors during the reporting period [1. Principal Business Activities During the Reporting Period](index=10&type=section&id=1.%20Principal%20Business%20Activities%20During%20the%20Reporting%20Period) In H1 2025, Jinling Pharmaceutical focused on pharmaceutical manufacturing and medical/eldercare services, achieving **RMB 1.60 billion** in revenue and **RMB 48.33 million** in net profit attributable to the parent company - In the first half of 2025, the company achieved total operating revenue of **RMB 1.60 billion**, operating profit of **RMB 60.49 million**, and net profit attributable to owners of the parent company of **RMB 48.33 million**[25](index=25&type=chunk) - The company's main businesses cover two major segments: pharmaceutical and medical device manufacturing, and medical and eldercare services, with key products including Mailuoning Injection/Oral Solution, Ferrous Succinate Tablets (Sulifei), Lentinan Injection, and Absorbable Gelatin Sponge[25](index=25&type=chunk) - The company's management model is headquarters-integrated management, with four business management centers for manufacturing, medical services, technological innovation, and marketing, and each operating unit functions as a cost-profit center[26](index=26&type=chunk) - Performance drivers primarily include brand advantage, improved product efficacy, and stable overall outpatient, emergency, and inpatient numbers at medical institutions[27](index=27&type=chunk) - In pharmaceutical manufacturing, the company's products cover cardiovascular and cerebrovascular, iron supplements, stomach medicines, and adjuvant oncology drugs, with Ferrous Succinate Tablets (Sulifei) having a significant competitive advantage[28](index=28&type=chunk) - In medical and eldercare services, Suqian Hospital is a Grade III Class A general hospital, Anqing Hospital is a Grade III general hospital, Meishan Hospital and Yizheng Hospital are Grade II Class A general hospitals; the Welfare Center is a five-star elderly care institution in Zhejiang Province[28](index=28&type=chunk) - Frequent industry policies promote high-quality development in the pharmaceutical sector, including optimizing centralized drug procurement, supporting innovative drug development, and improving the inheritance and innovation of traditional Chinese medicine[28](index=28&type=chunk)[29](index=29&type=chunk) - Accelerated population aging drives rapid growth in the silver economy, with its scale reaching **RMB 9 trillion** in H1 2025, accounting for **6.5% of GDP**[29](index=29&type=chunk) - Deepening medical insurance reform will achieve full coverage of DRG/DIP payment methods across national統籌 regions, reshaping the healthcare industry ecosystem[30](index=30&type=chunk) - The company's R&D investment in the first half of the year was **RMB 45.34 million**, a **20.51% year-on-year increase**; it completed registration applications for 3 varieties, including Sevelamer Carbonate for Oral Suspension, and applied for 7 invention patents, with 3 granted[32](index=32&type=chunk) [2. Core Competitiveness Analysis](index=12&type=section&id=2.%20Core%20Competitiveness%20Analysis) Jinling Pharmaceutical's core strengths lie in its brand, technology, production quality, hospital operation experience, and robust financial stability - The company owns the "Guiguan" China Well-known Trademark, and "Mailuoning Injection" and "Ferrous Succinate Tablets" are listed in the National Essential Drug List and National Medical Insurance Catalog, demonstrating significant brand advantage[33](index=33&type=chunk) - The company has a provincial enterprise technology center, university-enterprise joint laboratories, and a postdoctoral research workstation, possessing a high-level professional technical team and advanced hardware and software facilities, demonstrating strong technological innovation advantages[33](index=33&type=chunk) - All of the company's preparations have passed the national new GMP certification, accumulating extensive technical data and production experience, demonstrating production quality advantages[35](index=35&type=chunk) - The company controls four general hospitals and one medical-eldercare integration institution, possessing experience and capability in operating hospital projects[35](index=35&type=chunk) - The company's main business revenue is stable, with low debt ratio and debt scale, low financial leverage, and high financial stability[35](index=35&type=chunk) R&D Projects in Registration Process During the Reporting Period | Drug Name | Registration Category | Indications | Stage and Progress | | :--- | :--- | :--- | :--- | | Cicada Slough Cough Granules | Traditional Chinese Medicine Class 1.1 | Dispelling wind and clearing lung, relieving cough | Pre-application CDE communication stage | | Sevelamer Carbonate for Oral Suspension | Chemical Drug Class 3 | Control of hyperphosphatemia in chronic kidney disease | Application for production, under CDE review | | Elagolix Tablets | Chemical Drug Class 3 | Pain associated with endometriosis | Application for clinical trial, under CDE review | [3. Main Business Analysis](index=13&type=section&id=3.%20Main%20Business%20Analysis) The company's H1 2025 operating revenue decreased by **6.62%** year-on-year, mainly due to declines in medical services and chemical pharmaceutical revenue, while financial expenses increased by **51.18%** Key Financial Data Year-on-Year Change | Indicator | Current Period (RMB) | Prior Period (RMB) | YoY Change | Reason for Change | | :--- | :--- | :--- | :--- | :--- | | Operating Revenue | 1,601,071,008.21 | 1,714,541,843.46 | -6.62% | | | Operating Cost | 1,289,905,608.04 | 1,365,672,802.57 | -5.55% | | | Selling Expenses | 41,514,693.21 | 35,535,253.14 | 16.83% | | | Administrative Expenses | 183,261,110.04 | 181,532,142.45 | 0.95% | | | Financial Expenses | -4,189,256.35 | -8,580,277.89 | 51.18% | Decrease in interest income and increase in interest expense | | Income Tax Expense | 10,572,092.45 | 19,032,874.41 | -44.45% | Decrease in taxable income | | R&D Investment | 45,341,568.66 | 37,625,764.23 | 20.51% | | | Net Cash Flow from Operating Activities | 15,844,298.86 | 21,359,985.63 | -25.82% | | | Net Cash Flow from Investing Activities | -577,562,448.03 | -695,988,573.84 | 17.02% | | | Net Cash Flow from Financing Activities | -7,522,456.21 | 680,114,836.53 | -101.11% | Higher cash from investments absorbed in prior period | | Net Increase in Cash and Cash Equivalents | -569,223,041.43 | 5,535,664.25 | -10,382.83% | Decrease in cash from investments absorbed in current period | Operating Revenue Composition (By Industry, Product, Region) | Category | Item | Current Period Amount (RMB) | Proportion of Operating Revenue | Prior Period Amount (RMB) | Proportion of Operating Revenue | YoY Change | | :--- | :--- | :--- | :--- | :--- | :--- | :--- | | **By Industry** | Pharmaceutical Production and Sales | 776,500,856.38 | 48.50% | 815,632,707.56 | 47.57% | -4.80% | | | Medical Services | 807,599,029.60 | 50.44% | 878,265,092.71 | 51.22% | -8.05% | | **By Product** | Traditional Chinese Medicine | 257,448,090.16 | 16.08% | 254,462,705.05 | 14.84% | 1.17% | | | Chemical Pharmaceuticals | 507,321,589.91 | 31.69% | 546,404,189.18 | 31.87% | -7.15% | | | Medical Services | 807,599,029.60 | 50.44% | 878,265,092.71 | 51.22% | -8.05% | | **By Region** | East China Region | 1,483,843,573.34 | 92.68% | 1,541,635,356.00 | 89.92% | -3.75% | Industries, Products, or Regions Accounting for Over 10% of Company's Operating Revenue or Operating Profit | Category | Item | Operating Revenue (RMB) | Operating Cost (RMB) | Gross Margin | YoY Change in Operating Revenue | YoY Change in Operating Cost | YoY Change in Gross Margin | | :--- | :--- | :--- | :--- | :--- | :--- | :--- | :--- | | **By Industry** | Pharmaceutical Production and Sales | 776,500,856.38 | 526,391,343.51 | 32.21% | -4.80% | -8.98% | -8.82% | | | Medical Services | 807,599,029.60 | 737,267,148.51 | 8.71% | -8.05% | -4.18% | -5.44% | | **By Product** | Traditional Chinese Medicine | 257,448,090.16 | 206,718,374.14 | 19.70% | 1.17% | 5.19% | -9.78% | | | Chemical Pharmaceuticals | 507,321,589.91 | 319,672,969.37 | 36.99% | -7.15% | -14.01% | -9.99% | | | Medical Services | 807,599,029.60 | 737,267,148.51 | 8.71% | -8.05% | -4.18% | -5.44% | | **By Region** | East China Region | 1,483,843,573.33 | 1,211,923,655.41 | 18.33% | -3.98% | -6.82% | -0.49% | [4. Non-Principal Business Analysis](index=15&type=section&id=4.%20Non-Principal%20Business%20Analysis) Non-principal business profits, totaling **39.09%** of total profit, primarily stemmed from investment income and fair value changes, but these sources are less sustainable Non-Principal Business Analysis | Item | Amount (RMB) | Proportion of Total Profit | Reason for Formation | Sustainability | | :--- | :--- | :--- | :--- | :--- | | Investment Income | 11,824,341.53 | 19.39% | Securities investment income, long-term equity investment income, bank wealth management product income | No | | Gains/Losses from Changes in Fair Value | 12,013,263.09 | 19.70% | Fair value change gains from trading financial assets held at period-end | No | | Non-Operating Income | 720,443.13 | 1.18% | Mainly penalty income, etc | No | | Non-Operating Expenses | 221,742.26 | 0.36% | Mainly losses from impairment or disposal of non-current assets, etc | No | [5. Analysis of Assets and Liabilities](index=15&type=section&id=5.%20Analysis%20of%20Assets%20and%20Liabilities) At period-end, total assets were **RMB 6.05 billion**, a slight **0.56% decrease**, with cash and equivalents down **7.15%** and trading financial assets up **74.55%** to **RMB 1.23 billion** Significant Changes in Asset Composition | Item | Current Period-End Amount (RMB) | Proportion of Total Assets | Prior Year-End Amount (RMB) | Proportion of Total Assets | Change in Proportion | | :--- | :--- | :--- | :--- | :--- | :--- | | Cash and Cash Equivalents | 1,328,637,013.44 | 21.94% | 1,770,945,293.91 | 29.09% | -7.15% | | Accounts Receivable | 573,281,186.26 | 9.47% | 438,924,723.85 | 7.21% | 2.26% | | Inventories | 242,228,006.06 | 4.00% | 271,624,277.17 | 4.46% | -0.46% | | Fixed Assets | 1,382,899,136.97 | 22.84% | 1,396,190,053.42 | 22.93% | -0.09% | | Construction in Progress | 84,609,989.37 | 1.40% | 71,782,383.50 | 1.18% | 0.22% | | Contract Liabilities | 26,950,479.37 | 0.45% | 35,600,964.59 | 0.58% | -0.13% | | Long-Term Borrowings | 150,088,125.00 | 2.48% | 150,123,750.00 | 2.47% | 0.01% | Assets and Liabilities Measured at Fair Value | Item | Beginning Balance (RMB) | Gains/Losses from Fair Value Changes in Current Period (RMB) | Amount Purchased in Current Period (RMB) | Amount Sold in Current Period (RMB) | Ending Balance (RMB) | | :--- | :--- | :--- | :--- | :--- | :--- | | Trading Financial Assets | 706,046,500.54 | 12,013,263.09 | 1,171,200,000.00 | 656,851,353.84 | 1,232,408,409.79 | | Other Equity Instrument Investments | 586,084.34 | | | | 406,542.26 | | Total | 706,632,584.88 | 12,013,263.09 | 1,171,200,000.00 | 656,851,353.84 | 1,232,814,952.05 | Restricted Asset Information | Item | Period-End Carrying Amount (RMB) | Type of Restriction | Restriction Details | | :--- | :--- | :--- | :--- | | Cash and Cash Equivalents | 16,648,170.18 | Pledged as collateral | Bill deposit | | Cash and Cash Equivalents | 8,000,000.00 | Pledged as collateral | Letter of guarantee deposit | | Cash and Cash Equivalents | 28,000.00 | Frozen | ETC bank deposit | | Total | 24,676,170.18 | | | [6. Investment Analysis](index=17&type=section&id=6.%20Investment%20Analysis) The company's investment amount was **RMB 0**, a **100% decrease** year-on-year, with ongoing non-equity projects like Nanjing Meishan Hospital expansion and Hefei Jinling Tianyi Smart Elderly Care project in early stages Investment Amount During the Reporting Period | Investment Amount in Current Period (RMB) | Investment Amount in Prior Period (RMB) | Change Rate | | :--- | :--- | :--- | | 0.00 | 600,000,000.00 | -100.00% | Significant Non-Equity Investments in Progress | Project Name | Investment Method | Is it Fixed Asset Investment | Amount Invested in Current Period (RMB) | Cumulative Investment Amount as of Period-End (RMB) | Project Progress | | :--- | :--- | :--- | :--- | :--- | :--- | | Nanjing Meishan Hospital Expansion and Renovation Project | Self-built | Yes | 12,690,526.83 | 59,942,538.92 | N/A | | Hefei Jinling Tianyi Smart Elderly Care Project | Self-built | Yes | 1,372,493.00 | 287,300.00 | 2.00% | Securities Investment Information | Security Abbreviation | Beginning Carrying Amount (RMB) | Gains/Losses from Fair Value Changes in Current Period (RMB) | Period-End Carrying Amount (RMB) | | :--- | :--- | :--- | :--- | | Zijin Bank | 92,044,825.50 | 4,844,500.00 | 96,889,290.00 | Overall Use of Raised Funds | Total Raised Funds (RMB 10,000) | Net Raised Funds (RMB 10,000) | Total Raised Funds Used in Current Period (RMB 10,000) | Cumulative Raised Funds Used (RMB 10,000) | Proportion of Raised Funds Used at Period-End | | :--- | :--- | :--- | :--- | :--- | | 75,000 | 74,263.23 | 815.12 | 1,892.52 | 2.55% | - The "Hefei Jinling Tianyi Smart Elderly Care Project" is in the preliminary preparation stage, and the "Common Production Platform for Core APIs and High-End Pharmaceutical Intermediates Project" is in the engineering planning and design stage, both behind schedule[57](index=57&type=chunk) [7. Significant Asset and Equity Sales](index=20&type=section&id=7.%20Significant%20Asset%20and%20Equity%20Sales) The company did not engage in any significant asset or equity sales during the reporting period - The company did not sell any significant assets during the reporting period[60](index=60&type=chunk) - The company did not sell any significant equity during the reporting period[61](index=61&type=chunk) [8. Analysis of Major Controlled and Invested Companies](index=21&type=section&id=8.%20Analysis%20of%20Major%20Controlled%20and%20Invested%20Companies) Major controlled subsidiaries like Nanjing Gulou Hospital Group Suqian Hospital and Nanjing Meishan Hospital are crucial to the company's medical services segment and net profit Major Subsidiaries and Invested Companies with Over 10% Impact on Company's Net Profit | Company Name | Company Type | Principal Business | Registered Capital (RMB) | Total Assets (RMB) | Net Assets (RMB) | Operating Revenue (RMB) | Operating Profit (RMB) | Net Profit (RMB) | | :--- | :--- | :--- | :--- | :--- | :--- | :--- | :--- | :--- | | Nanjing Gulou Hospital Group Suqian Hospital Co., Ltd. | Subsidiary | Medical Services | 80,000,000 | 1,670,902,539.74 | 1,335,707,645.99 | 652,590,341.66 | 2,797,968.30 | 2,112,066.93 | | Nanjing Meishan Hospital Co., Ltd. | Subsidiary | Medical Services | 28,571,400 | 969,057,942.39 | 820,834,895.50 | 208,407,158.42 | 3,986,039.21 | 3,255,189.11 | | Nanjing Gulou Hospital Group Yizheng Hospital Co., Ltd. (Consolidated) | Subsidiary | Medical Services | 33,319,831 | 400,761,986.86 | 253,839,438.66 | 190,399,888.59 | 1,667,303.47 | 1,892,231.92 | - The company neither acquired nor disposed of any subsidiaries during the reporting period[63](index=63&type=chunk) [9. Information on Structured Entities Controlled by the Company](index=21&type=section&id=9.%20Information%20on%20Structured%20Entities%20Controlled%20by%20the%20Company) The company did not control any structured entities during the reporting period - The company did not control any structured entities during the reporting period[64](index=64&type=chunk) [10. Risks Faced by the Company and Countermeasures](index=21&type=section&id=10.%20Risks%20Faced%20by%20the%20Company%20and%20Countermeasures) The company faces risks from policy changes, market competition, raw material prices, goodwill impairment, R&D, quality control, and environmental protection, with corresponding mitigation strategies in place - The company faces risks from industry policy changes, with countermeasures including closely monitoring policy trends and adjusting business and management models[64](index=64&type=chunk) - The company faces market competition risks, with countermeasures including continuously improving product quality, enhancing new product R&D capabilities, and strengthening sales networks and brand building[64](index=64&type=chunk) - The company faces risks from raw material price fluctuations, with countermeasures including strengthening market research, optimizing procurement processes, and stocking common bulk raw materials[65](index=65&type=chunk) - The company faces goodwill impairment risk, with countermeasures including strengthening control over acquired companies, expanding business scale, and improving efficiency[66](index=66&type=chunk) - The company faces risks in drug R&D and consistency evaluation, with countermeasures including improving R&D capabilities, carefully selecting projects, and focusing efforts on promoting R&D innovation[66](index=66&type=chunk) - The company faces quality control risks, with countermeasures including continuously increasing technological investment, accelerating capacity upgrades, and completing GMP certification improvements[67](index=67&type=chunk) - The company faces environmental protection risks, with countermeasures including increasing investment in environmental management system construction and improving the internal environmental supervision system[67](index=67&type=chunk) [11. Formulation and Implementation of Market Value Management System and Valuation Enhancement Plan](index=22&type=section&id=11.%20Formulation%20and%20Implementation%20of%20Market%20Value%20Management%20System%20and%20Valuation%20Enhancement%20Plan) The company did not formulate a market value management system or disclose a valuation enhancement plan during the reporting period - The company did not formulate a market value management system during the reporting period[68](index=68&type=chunk) - The company did not disclose a valuation enhancement plan during the reporting period[68](index=68&type=chunk) [12. Implementation of "Dual Improvement in Quality and Returns" Action Plan](index=22&type=section&id=12.%20Implementation%20of%20%22Dual%20Improvement%20in%20Quality%20and%20Returns%22%20Action%20Plan) The company did not disclose an announcement regarding the "Dual Improvement in Quality and Returns" action plan during the reporting period - The company did not disclose an announcement regarding the "Dual Improvement in Quality and Returns" action plan during the reporting period[68](index=68&type=chunk) [Part IV Corporate Governance, Environment, and Society](index=22&type=section&id=Part%20IV%20Corporate%20Governance%2C%20Environment%2C%20and%20Society) This section covers changes in the company's governance structure, profit distribution, environmental disclosures, and social responsibility initiatives [1. Changes in Directors, Supervisors, and Senior Management](index=22&type=section&id=1.%20Changes%20in%20Directors%2C%20Supervisors%2C%20and%20Senior%20Management) Changes in the company's directors, supervisors, and senior management occurred during the reporting period, though specific details are not provided here - Changes in the company's directors, supervisors, and senior management are applicable[69](index=69&type=chunk) [2. Profit Distribution and Capital Reserve Conversion to Share Capital in Current Period](index=23&type=section&id=2.%20Profit%20Distribution%20and%20Capital%20Reserve%20Conversion%20to%20Share%20Capital%20in%20Current%20Period) The company plans not to distribute cash dividends, bonus shares, or convert capital reserves into share capital for the half-year period - The company plans not to distribute cash dividends, bonus shares, or convert capital reserves into share capital for the half-year period[71](index=71&type=chunk) [3. Implementation of Equity Incentive Plans, Employee Stock Ownership Plans, or Other Employee Incentive Measures](index=23&type=section&id=3.%20Implementation%20of%20Equity%20Incentive%20Plans%2C%20Employee%20Stock%20Ownership%20Plans%2C%20or%20Other%20Employee%20Incentive%20Measures) The company had no equity incentive plans, employee stock ownership plans, or other employee incentive measures in place during the reporting period - The company had no equity incentive plans, employee stock ownership plans, or other employee incentive measures and their implementation during the reporting period[72](index=72&type=chunk) [4. Environmental Information Disclosure](index=23&type=section&id=4.%20Environmental%20Information%20Disclosure) The company and four major subsidiaries are listed as legally required environmental information disclosure enterprises, with relevant query indexes provided - The company and its major subsidiaries, totaling **4 entities**, are included in the list of enterprises legally required to disclose environmental information[73](index=73&type=chunk) - The listed enterprises include Jinling Pharmaceutical Co., Ltd. Nanjing Jinling Pharmaceutical Factory, Nanjing Gulou Hospital Group Yizheng Hospital Co., Ltd., Nanjing Gulou Hospital Group Anqing Petrochemical Hospital Co., Ltd., and Chizhou Dongsheng Pharmaceutical Co., Ltd[73](index=73&type=chunk) [5. Social Responsibility](index=23&type=section&id=5.%20Social%20Responsibility) The company actively fulfills social responsibilities through employee blood donations, community medical services, and green initiatives like energy saving, emission reduction, and sustainable planting - **395 employees** participated in voluntary blood donation, with a total blood volume of **119,900 milliliters**[74](index=74&type=chunk) - Jinling Pharmaceutical Factory saved **RMB 170,000** annually, conserved over **a thousand tons of water**, and reduced carbon emissions by **hundreds of tons** through smart electricity use and solar street light upgrades, resulting in year-on-year decreases in energy consumption and carbon emissions[74](index=74&type=chunk) - Fuzhou Meifeng Pharmaceutical Factory achieved results in exhaust gas treatment and promoting green packaging, with both energy consumption and carbon emissions decreasing[74](index=74&type=chunk) [Part V Significant Matters](index=24&type=section&id=Part%20V%20Significant%20Matters) This section details unfulfilled commitments, related party transactions, litigation, and other significant events impacting the company [1. Commitments Fulfilled and Overdue Unfulfilled by Actual Controller, Shareholders, Related Parties, Acquirers, and the Company During and as of the End of the Reporting Period](index=24&type=section&id=1.%20Commitments%20Fulfilled%20and%20Overdue%20Unfulfilled%20by%20Actual%20Controller%2C%20Shareholders%2C%20Related%20Parties%2C%20Acquirers%2C%20and%20the%20Company%20During%20and%20as%20of%20the%20End%20of%20the%20Reporting%20Period) Huzhou Guoxin Materials Co., Ltd. and Chen Guoqiang failed to fulfill a **RMB 60 million** net profit commitment for Welfare Company, with a **RMB 31.01 million** shortfall, leading to ongoing litigation - Huzhou Guoxin Materials Co., Ltd. and Chen Guoqiang failed to fulfill their performance commitment for Welfare Company's cumulative net profit of not less than **RMB 60 million** for the three years from 2018 to 2020[76](index=76&type=chunk) - Welfare Center's cumulative net profit for 2018-2020 was **RMB 28.99 million**, resulting in an unfulfilled performance commitment net profit difference of **RMB 31.01 million**[76](index=76&type=chunk) - The company has applied to the court for enforcement, but the execution has been suspended due to the acceptance of Guoxin Materials' bankruptcy liquidation application[77](index=77&type=chunk) [2. Non-Operating Fund Occupation by Controlling Shareholders and Other Related Parties](index=25&type=section&id=2.%20Non-Operating%20Fund%20Occupation%20by%20Controlling%20Shareholders%20and%20Other%20Related%20Parties) The company reported no non-operating fund occupation by controlling shareholders or other related parties during the reporting period - The company reported no non-operating fund occupation by controlling shareholders or other related parties during the reporting period[78](index=78&type=chunk) [3. Irregular External Guarantees](index=25&type=section&id=3.%20Irregular%20External%20Guarantees) The company had no irregular external guarantees during the reporting period - The company had no irregular external guarantees during the reporting period[79](index=79&type=chunk) [4. Appointment and Dismissal of Accounting Firms](index=25&type=section&id=4.%20Appointment%20and%20Dismissal%20of%20Accounting%20Firms) The company's semi-annual financial report was not audited - The company's semi-annual financial report was not audited[80](index=80&type=chunk) [5. Board of Directors' and Supervisory Board's Explanation on "Non-Standard Audit Report" for the Current Period](index=25&type=section&id=5.%20Board%20of%20Directors'%20and%20Supervisory%20Board's%20Explanation%20on%20%22Non-Standard%20Audit%20Report%22%20for%20the%20Current%20Period) The company reported no "non-standard audit report" issued by the accounting firm during the current period - The company reported no "non-standard audit report" issued by the accounting firm during the reporting period[81](index=81&type=chunk) [6. Board of Directors' Explanation on "Non-Standard Audit Report" for the Prior Year](index=26&type=section&id=6.%20Board%20of%20Directors'%20Explanation%20on%20%22Non-Standard%20Audit%20Report%22%20for%20the%20Prior%20Year) The company provided no explanation regarding a "non-standard audit report" for the prior year during the reporting period - The company provided no explanation regarding a "non-standard audit report" for the prior year during the reporting period[82](index=82&type=chunk) [7. Bankruptcy and Reorganization Matters](index=26&type=section&id=7.%20Bankruptcy%20and%20Reorganization%20Matters) The company had no bankruptcy and reorganization matters during the reporting period - The company had no bankruptcy and reorganization matters during the reporting period[82](index=82&type=chunk) [8. Litigation Matters](index=26&type=section&id=8.%20Litigation%20Matters) The company had no significant litigation or arbitration matters during the current reporting period - The company had no significant litigation or arbitration matters during the current reporting period[83](index=83&type=chunk) [9. Penalties and Rectification](index=26&type=section&id=9.%20Penalties%20and%20Rectification) The company reported no penalties or rectification situations during the reporting period - The company reported no penalties or rectification situations during the reporting period[83](index=83&type=chunk) [10. Integrity Status of the Company, its Controlling Shareholder, and Actual Controller](index=26&type=section&id=10.%20Integrity%20Status%20of%20the%20Company%2C%20its%20Controlling%20Shareholder%2C%20and%20Actual%20Controller) The company reported no integrity issues concerning itself, its controlling shareholder, or its actual controller during the reporting period - The company reported no integrity issues concerning itself, its controlling shareholder, or its actual controller during the reporting period[84](index=84&type=chunk) [11. Significant Related Party Transactions](index=26&type=section&id=11.%20Significant%20Related%20Party%20Transactions) The company engaged in routine related party transactions, primarily involving procurement and sales of goods and services with Nanjing Pharmaceutical Co., Ltd. and its subsidiaries, all within approved limits Related Party Transactions Related to Ordinary Operations | Related Party | Type of Related Party Transaction | Content of Related Party Transaction | Transaction Amount (RMB 10,000) | Approved Transaction Limit (RMB 10,000) | Exceeded Limit | | :--- | :--- | :--- | :--- | :--- | :--- | | Nanjing Pharmaceutical Co., Ltd. and its subsidiaries | Procurement and Acceptance of Services | Goods and Services | 1,9232.04 | 6,0000 | No | | Nanjing Pharmaceutical Co., Ltd. and its subsidiaries | Sales and Provision of Services | Goods and Services | 3,956.06 | 1,0000 | No | | Nanjing Yitong Pharmaceutical Co., Ltd. | Sales and Provision of Services | Goods and Services | 9,616.14 | 2,5000 | No | | Nanjing Adketen Biomedical Co., Ltd. | Sales and Provision of Services | Goods and Services | 296.05 | 800 | No | - The company did not engage in related party transactions involving asset or equity acquisitions/disposals during the reporting period[86](index=86&type=chunk) - The company did not engage in related party transactions involving joint external investments during the reporting period[87](index=87&type=chunk) - The company had no related party creditor-debtor relationships during the reporting period[88](index=88&type=chunk) - There were no deposits, loans, credit lines, or other financial transactions between the company and related financial companies[89](index=89&type=chunk) - There were no deposits, loans, credit lines, or other financial transactions between the company's controlled financial company and related parties[90](index=90&type=chunk) - The company had no other significant related party transactions during the reporting period[91](index=91&type=chunk) [12. Significant Contracts and Their Performance](index=28&type=section&id=12.%20Significant%20Contracts%20and%20Their%20Performance) The company had no significant entrustment or contracting arrangements, but engaged in leasing activities with **RMB 2.34 million** in income and **RMB 0.93 million** in expenses, and entrusted wealth management totaling **RMB 1.44 billion** - The company had no entrustment arrangements during the reporting period[92](index=92&type=chunk) - The company had no contracting arrangements during the reporting period[93](index=93&type=chunk) - During the current reporting period, the company generated **RMB 2.34 million** in leasing income, accounting for **4.64%** of its net profit for the period; leasing expenses amounted to **RMB 0.93 million**[94](index=94&type=chunk) - The company had no leasing projects that generated profits or losses exceeding **10%** of the company's total profit during the reporting period[94](index=94&type=chunk) - The company had no significant guarantee situations during the reporting period[95](index=95&type=chunk) Entrusted Wealth Management | Specific Type | Source of Entrusted Wealth Management Funds | Amount of Entrusted Wealth Management (RMB 10,000) | Unmatured Balance (RMB 10,000) | Overdue Unrecovered Amount (RMB 10,000) | | :--- | :--- | :--- | :--- | :--- | | Bank Wealth Management Products | Own Funds | 79,620 | 69,120 | 0 | | Bank Wealth Management Products | Raised Funds | 64,000 | 68,000 | 0 | | Total | | 143,620 | 137,120 | 0 | - The company had no high-risk entrusted wealth management situations with significant individual amounts or low safety and liquidity during the reporting period[97](index=97&type=chunk) - The company had no entrusted wealth management where principal was expected to be unrecoverable or other impairment-causing situations during the reporting period[98](index=98&type=chunk) - The company had no other significant contracts during the reporting period[98](index=98&type=chunk) [13. Explanation of Other Significant Matters](index=29&type=section&id=13.%20Explanation%20of%20Other%20Significant%20Matters) Other significant matters include cash management with idle funds, a court ruling on a re-trial application, projected related party transactions, liquidation of an investment fund, director resignation, and new drug registration approvals - The company used idle raised funds for cash management and own funds for entrusted wealth management[98](index=98&type=chunk) - The company received a civil ruling from the Jiangsu Provincial High People's Court rejecting the re-trial application of Jinling Pharmaceutical Co., Ltd., Huzhou Guoxin Materials Co., Ltd., and Chen Guoqiang[98](index=98&type=chunk) - The company projected its ordinary related party transactions for 2025[98](index=98&type=chunk) - The company's investment in Nanjing Xingong Medical Industry Investment Fund Partnership (Limited Partnership) is planned for liquidation and deregistration, involving a related party transaction[98](index=98&type=chunk) - A company director resigned[98](index=98&type=chunk) - The company's branch, Nanjing Jinling Pharmaceutical Factory, received acceptance notices for Sevelamer Carbonate for Oral Suspension and Elagolix Tablets[99](index=99&type=chunk) [14. Significant Matters of Company Subsidiaries](index=29&type=section&id=14.%20Significant%20Matters%20of%20Company%20Subsidiaries) The company's controlled subsidiary, Chizhou Dongsheng Pharmaceutical Co., Ltd., received approval for its chemical API marketing application - The company's controlled subsidiary, Chizhou Dongsheng Pharmaceutical Co., Ltd., received an approval notice for its chemical API marketing application[100](index=100&type=chunk) [Part VI Share Changes and Shareholder Information](index=30&type=section&id=Part%20VI%20Share%20Changes%20and%20Shareholder%20Information) This section details changes in share capital, shareholder structure, and holdings of directors, supervisors, and senior management [1. Share Change Information](index=30&type=section&id=1.%20Share%20Change%20Information) The company's total share capital remained unchanged at **623.71 million shares**, with a slight increase in restricted shares due to the buyback and cancellation of some equity incentive restricted stocks Share Change Information | Item | Quantity Before Change (shares) | Increase/Decrease in Current Change (shares) | Quantity After Change (shares) | | :--- | :--- | :--- | :--- | | I. Restricted Shares | 33,349,166 | 39,275 | 33,388,441 | | Of which: Other Domestic Shares | 1,902,625 | 39,275 | 1,941,900 | | II. Unrestricted Shares | 590,359,462 | -39,275 | 590,320,187 | | III. Total Shares | 623,708,628 | 0 | 623,708,628 | - The reason for the share change was the company's completion of the buyback and cancellation of some equity incentive restricted shares on November 15, 2024, leading to a decrease in the total number of shares held by senior management and an increase in senior management restricted shares[104](index=104&type=chunk) Restricted Share Change Information | Shareholder Name | Beginning Restricted Shares (shares) | Increase in Restricted Shares in Current Period (shares) | Period-End Restricted Shares (shares) | Reason for Restriction | | :--- | :--- | :--- | :--- | :--- | | Nanjing Xingong Investment Group Co., Ltd. | 31,446,541 | 0 | 31,446,541 | Restricted shares after initial public offering | | Wang Yang | 64,750 | 29,750 | 94,500 | Senior management restricted shares, equity incentive restricted shares | | Jia Mingyi | 48,000 | 3,225 | 51,225 | Senior management restricted shares, equity incentive restricted shares | | Li Jian | 48,000 | 3,150 | 51,150 | Senior management restricted shares, equity incentive restricted shares | | Li Quan | 48,000 | 3,150 | 51,150 | Senior management restricted shares, equity incentive restricted shares | | Total | 32,015,066 | 39,275 | 32,054,341 | | [2. Securities Issuance and Listing](index=32&type=section&id=2.%20Securities%20Issuance%20and%20Listing) The company had no securities issuance or listing activities during the reporting period - The company had no securities issuance or listing activities during the reporting period[108](index=108&type=chunk) [3. Number of Shareholders and Shareholding Structure](index=32&type=section&id=3.%20Number%20of%20Shareholders%20and%20Shareholding%20Structure) At period-end, the company had **35,441** common shareholders, with Nanjing Xingong Investment Group Co., Ltd. as the controlling shareholder, holding **41.59%** of shares - Total number of common shareholders at the end of the reporting period: **35,441**[109](index=109&type=chunk) Shareholding Information of Shareholders Holding 5% or More or Top 10 Shareholders | Shareholder Name | Shareholder Nature | Shareholding Proportion | Shares Held at Period-End (shares) | Restricted Shares Held (shares) | Unrestricted Shares Held (shares) | | :--- | :--- | :--- | :--- | :--- | :--- | | Nanjing Xingong Investment Group Co., Ltd. | State-owned Legal Person | 41.59% | 259,390,380 | 31,446,541 | 227,943,839 | | Fuzhou Investment Management Co., Ltd. | State-owned Legal Person | 3.69% | 23,003,700 | 0 | 23,003,700 | | Hefei Industrial Investment Holding Co., Ltd. | State-owned Legal Person | 1.56% | 9,711,271 | 0 | 9,711,271 | | Zhejiang International Trade Group Co., Ltd. | State-owned Legal Person | 1.00% | 6,224,865 | 0 | 6,224,865 | | Si Youshan | Domestic Natural Person | 0.94% | 5,868,700 | 0 | 5,868,700 | | Nanjing Kecheng Software Technology Co., Ltd. | Domestic Non-State-owned Legal Person | 0.82% | 5,095,589 | 0 | 5,095,589 | | Nanjing Xiechen Electronic Technology Co., Ltd. | Domestic Non-State-owned Legal Person | 0.59% | 3,706,761 | 0 | 3,706,761 | | Cheng Rong | Domestic Natural Person | 0.58% | 3,600,000 | 0 | 3,600,000 | | Chen Guomin | Domestic Natural Person | 0.42% | 2,632,500 | 0 | 2,632,500 | | Liu Ping | Domestic Natural Person | 0.40% | 2,479,500 | 0 | 2,479,500 | - Nanjing Xingong Investment Group Co., Ltd. is the controlling shareholder of the company[110](index=110&type=chunk) - Shareholders Cheng Rong and Chen Guomin hold company shares through margin trading and securities lending business[110](index=110&type=chunk) [4. Changes in Shareholdings of Directors, Supervisors, and Senior Management](index=34&type=section&id=4.%20Changes%20in%20Shareholdings%20of%20Directors%2C%20Supervisors%2C%20and%20Senior%20Management) The shareholdings of the company's directors, supervisors, and senior management remained unchanged during the reporting period - The shareholdings of the company's directors, supervisors, and senior management remained unchanged during the reporting period[111](index=111&type=chunk) [5. Changes in Controlling Shareholder or Actual Controller](index=34&type=section&id=5.%20Changes%20in%20Controlling%20Shareholder%20or%20Actual%20Controller) The company's controlling shareholder and actual controller remained unchanged during the reporting period - The company's controlling shareholder remained unchanged during the reporting period[112](index=112&type=chunk) - The company's actual controller remained unchanged during the reporting period[112](index=112&type=chunk) [6. Preferred Share Information](index=35&type=section&id=6.%20Preferred%20Share%20Information) The company had no preferred shares during the reporting period - The company had no preferred shares during the reporting period[113](index=113&type=chunk) [Part VII Bond-Related Information](index=36&type=section&id=Part%20VII%20Bond-Related%20Information) This section confirms the absence of any bond-related matters for the company during the reporting period [Bond-Related Information](index=36&type=section&id=Bond-Related%20Information) The company had no bond-related matters during the reporting period - The company had no bond-related matters during the reporting period[115](index=115&type=chunk) [Part VIII Financial Report](index=37&type=section&id=Part%20VIII%20Financial%20Report) This section presents the company's unaudited semi-annual financial statements, including balance sheets, income statements, cash flow statements, and statements of changes in equity [1. Audit Report](index=37&type=section&id=1.%20Audit%20Report) The company's semi-annual financial report was not audited - The company's semi-annual financial report was not audited[117](index=117&type=chunk) [2. Financial Statements](index=37&type=section&id=2.%20Financial%20Statements) This section provides Jinling Pharmaceutical's H1 2025 consolidated and parent company balance sheets, income statements, cash flow statements, and statements of changes in owner's equity Consolidated Balance Sheet (Period-End) | Item | Period-End Balance (RMB) | | :--- | :--- | | Cash and Cash Equivalents | 1,328,637,013.44 | | Trading Financial Assets | 1,232,408,409.79 | | Accounts Receivable | 573,281,186.26 | | Inventories | 242,228,006.06 | | Fixed Assets | 1,382,899,136.97 | | Total Assets | 6,054,547,027.24 | | Notes Payable | 55,493,900.56 | | Accounts Payable | 486,478,831.83 | | Contract Liabilities | 26,950,479.37 | | Long-Term Borrowings | 150,088,125.00 | | Total Liabilities | 1,231,534,684.49 | | Total Equity Attributable to Owners of the Parent Company | 3,772,432,638.51 | | Total Equity | 4,823,012,342.75 | Consolidated Income Statement (Current Period) | Item | Current Period Amount (RMB) | | :--- | :--- | | Total Operating Revenue | 1,601,071,008.21 | | Operating Profit | 60,490,316.90 | | Total Profit | 60,989,017.77 | | Net Profit | 50,416,925.32 | | Net Profit Attributable to Shareholders of the Parent Company | 48,333,532.45 | | Basic Earnings Per Share (RMB/share) | 0.0777 | | Diluted Earnings Per Share (RMB/share) | 0.0777 | Consolidated Cash Flow Statement (Current Period) | Item | Current Period Amount (RMB) | | :--- | :--- | | Net Cash Flow from Operating Activities | 15,844,298.86 | | Net Cash Flow from Investing Activities | -577,562,448.03 | | Net Cash Flow from Financing Activities | -7,522,456.21 | | Net Increase in Cash and Cash Equivalents | -569,223,041.43 | | Period-End Balance of Cash and Cash Equivalents | 1,012,144,925.99 | [3. Company Basic Information](index=55&type=section&id=3.%20Company%20Basic%20Information) Jinling Pharmaceutical Co., Ltd., established on September 8, 1998, with a registered capital of **RMB 623.71 million**, primarily engages in pharmaceutical manufacturing and medical/eldercare services, controlled by Nanjing Xingong Investment Group - Jinling Pharmaceutical Co., Ltd. was established on September 8, 1998, with a registered capital of **RMB 200 million**[151](index=151&type=chunk) - The company's registered capital has undergone multiple capital increases and buyback cancellations, with the latest registered capital being **RMB 623.71 million**[156](index=156&type=chunk) - The company primarily engages in pharmaceutical and medical device manufacturing, sales, and medical and eldercare services[157](index=157&type=chunk) - The company's parent company is Nanjing Xingong Investment Group Co., Ltd., and the ultimate controlling party is Nanjing Municipal People's Government State-owned Assets Supervision and Administration Commission[157](index=157&type=chunk) [4. Basis of Financial Statement Preparation](index=56&type=section&id=4.%20Basis%20of%20Financial%20Statement%20Preparation) These financial statements are prepared in accordance with the Accounting Standards for Business Enterprises and relevant regulations of the China Securities Regulatory Commission, on a going concern basis - These financial statements are prepared in accordance with the Accounting Standards for Business Enterprises promulgated by the Ministry of Finance and the relevant provisions of the China Securities Regulatory Commission's "No. 15 Rules for Information Disclosure by Companies Issuing Securities Publicly – General Provisions on Financial Reports"[158](index=158&type=chunk) - These financial statements are prepared on a going concern basis[159](index=159&type=chunk) [5. Significant Accounting Policies and Estimates](index=57&type=section&id=5.%20Significant%20Accounting%20Policies%20and%20Estimates) This section details the company's accounting policies and estimates, including financial instrument classification, impairment provisions, fixed asset depreciation, R&D capitalization, and revenue recognition, all compliant with enterprise accounting standards - These financial statements comply with the requirements of the Accounting Standards for Business Enterprises promulgated by the Ministry of Finance, truly and completely reflecting the company's financial position, operating results, and cash flows[161](index=161&type=chunk) - The company uses **RMB** as its bookkeeping currency, and its operating cycle is **12 months**[163](index=163&type=chunk)[164](index=164&type=chunk) - Financial assets are classified at initial recognition as: financial assets measured at amortized cost, financial assets measured at fair value through other comprehensive income, and financial assets measured at fair value through profit or loss[183](index=183&type=chunk) - The company accrues expected credit losses for accounts receivable, other receivables, etc., with bad debt provision rates varying by aging: **2.00%** for within one year, and **100.00%** for over three years[215](index=215&type=chunk) - Depreciation of fixed assets is calculated using the straight-line method, with depreciation periods of **20-50 years** for buildings and **5-15 years** for machinery and equipment[283](index=283&type=chunk) - R&D expenditures are divided into research and development phases; research phase expenditures are recognized in current profit or loss, while development phase expenditures meeting specific conditions can be capitalized as intangible assets[299](index=299&type=chunk) - Revenue recognition principle is to recognize revenue when performance obligations in the contract are satisfied, i.e., when the customer obtains control of the related goods or services[310](index=310&type=chunk) [6. Taxes](index=88&type=section&id=6.%20Taxes) This section lists the company's main tax types and rates, including VAT, urban maintenance and construction tax, corporate income tax, and surcharges, with certain subsidiaries enjoying high-tech enterprise and small-profit enterprise tax incentives Major Tax Types and Rates | Tax Type | Tax Base | Tax Rate | | :--- | :--- | :--- | | Value-Added Tax (VAT) | Value added from sales of goods or provision of taxable labor/services | 1%、3%、5%、6%、9%、13% | | Urban Maintenance and Construction Tax | Actual turnover tax paid | 5%、7% | | Corporate Income Tax | Taxable income | 15%、20%、25% | | Education Surcharge | Actual turnover tax paid | 3% | | Local Education Surcharge | Actual turnover tax paid | 2% | | Property Tax | Assessed on value: 1.2% of remaining value after a one-time 30% deduction from original property value; Assessed on rent: 12% of rental income | 1.2%、12% | - Jinling Pharmaceutical Co., Ltd. and Chizhou Dongsheng Pharmaceutical Co., Ltd. are recognized as high-tech enterprises, with corporate income tax rates reduced to **15%** for three years starting from 2023[342](index=342&type=chunk)[343](index=343&type=chunk) - Medical services provided by medical institutions and elderly care services provided by elderly care institutions are exempt from VAT[341](index=341&type=chunk) - Some subsidiaries enjoy corporate income tax benefits for small and micro-profit enterprises, paying corporate income tax at a **20%** rate[343](index=343&type=chunk) [7. Notes to Consolidated Financial Statement Items](index=89&type=section&id=7.%20Notes%20to%20Consolidated%20Financial%20Statement%20Items) This section details period-end balances and changes for consolidated financial statement items, including cash, trading financial assets (**RMB 1.23 billion**), accounts receivable (**RMB 573 million**), and goodwill (**RMB 329 million** original value, **RMB 266 million** impaired) Cash and Cash Equivalents | Item | Period-End Balance (RMB) | Beginning Balance (RMB) | | :--- | :--- | :--- | | Cash on Hand | 34,316.07 | 64,558.20 | | Bank Deposits | 1,298,963,088.39 | 1,747,341,907.93 | | Other Cash and Cash Equivalents | 29,639,608.98 | 23,538,827.78 | | Total | 1,328,637,013.44 | 1,770,945,293.91 | Trading Financial Assets | Item | Period-End Balance (RMB) | Beginning Balance (RMB) | | :--- | :--- | :--- | | Equity Instrument Investments | 96,889,290.00 | 92,044,825.50 | | Wealth Management Products | 1,135,519,119.79 | 614,001,675.04 | | Total | 1,232,408,409.79 | 706,046,500.54 | Accounts Receivable by Aging | Aging | Period-End Carrying Amount (RMB) | | :--- | :--- | | Within 1 year (inclusive) | 573,480,700.24 | | 1 to 2 years | 18,072,965.77 | | 2 to 3 years | 3,735,552.52 | | Over 3 years | 10,671,112.76 | | Total | 605,960,331.29 | Inventory Classification | Item | Period-End Carrying Amount (RMB) | Inventory Impairment Provision (RMB) | Period-End Carrying Value (RMB) | | :--- | :--- | :--- | :--- | | Raw Materials | 25,288,153.57 | 22,300.89 | 25,265,852.68 | | Work in Progress | 81,921,234.06 | 0 | 81,921,234.06 | | Finished Goods | 136,876,196.43 | 1,973,421.04 | 134,902,775.39 | | Total | 244,223,727.99 | 1,995,721.93 | 242,228,006.06 | Fixed Assets Information (Carrying Value) | Item | Period-End Carrying Value (RMB) | | :--- | :--- | | Buildings and Structures | 965,119,884.31 | | Machinery and Equipment | 373,139,926.32 | | Transportation Equipment | 5,592,502.16 | | Other Equipment | 38,941,758.17 | | Total | 1,382,794,070.96 | Goodwill Original Carrying Amount | Name of Investee | Beginning Balance (RMB) | Period-End Balance (RMB) | | :--- | :--- | :--- | | Nanjing Gulou Hospital Group Suqian Hospital Co., Ltd. | 18,045,830.93 | 18,045,830.93 | | Nanjing Gulou Hospital Group Yizheng Hospital Co., Ltd. | 24,838,091.83 | 24,838,091.83 | | Nanjing Gulou Hospital Group Anqing Petrochemical Hospital Co., Ltd. | 50,918,446.07 | 50,918,446.07 | | Huzhou Social Welfare Center Development Co., Ltd. | 104,225,472.76 | 104,225,472.76 | | Chizhou Dongsheng Pharmaceutical Co., Ltd. | 9,285,710.86 | 9,285,710.86 | | Nanjing Meishan Hospital Co., Ltd. | 121,391,986.07 | 121,391,986.07 | | Total | 328,705,538.52 | 328,705,538.52 | Goodwill Impairment Provision | Name of Investee | Beginning Balance (RMB) | Period-End Balance (RMB) | | :--- | :--- | :--- | | Nanjing Gulou Hospital Group Yizheng Hospital Co., Ltd. | 24,838,091.83 | 24,838,091.83 | | Nanjing Gulou Hospital Group Anqing Petrochemical Hospital Co., Ltd. | 50,918,446.07 | 50,918,446.07 | | Huzhou Social Welfare Center Development Co., Ltd. | 104,225,472.76 | 104,225,472.76 | | Chizhou Dongsheng Pharmaceutical Co., Ltd. | 9,285,710.86 | 9,285,710.86 | | Nanjing Meishan Hospital Co., Ltd. | 77,018,945.37 | 77,018,945.37 | | Total | 266,286,666.89 | 266,286,666.89 | Employee Compensation Payable | Item | Beginning Balance (RMB) | Increase in Current Period (RMB) | Decrease in Current Period (RMB) | Period-End Balance (RMB) | | :--- | :--- | :--- | :--- | :--- | | I. Short-Term Compensation | 107,541,380.86 | 527,174,296.41 | 565,544,941.41 | 69,170,735.86 | | II. Post-Employment Benefits - Defined Contribution Plans | 9,365,416.29 | 50,366,144.21 | 50,359,271.09 | 9,372,289.41 | | III. Termination Benefits | 275,097.00 | 820,468.00 | 1,095,565.00 | 0 | | Total | 117,181,894.15 | 578,360,908.62 | 616,999,777.50 | 78,543,025.27 | Operating Revenue and Operating Cost | Item | Current Period Revenue (RMB) | Current Period Cost (RMB) | | :--- | :--- | :--- | | Principal Business | 1,587,071,986.23 | 1,284,061,843.37 | | Other Businesses | 13,999,021.98 | 5,843,764.67 | | Total | 1,601,071,008.21 | 1,289,905,608.04 | Investment Income | Item | Current Period Amount (RMB) | | :--- | :--- | | Investment Income from Long-Term Equity Investments Accounted for by Equity Method | 2,921,215.85 | | Investment Income from Trading Financial Assets During Holding Period | 3,229,643.00 | | Investment Income from Wealth Management Products | 5,672,695.26 | | Total | 11,824,341.53 | [8. R&D Expenditures](index=145&type=section&id=8.%20R%26D%20Expenditures) The company's total R&D expenditure for the current period was **RMB 45.34 million**, all expensed, representing a **20.51% year-on-year increase**, reflecting a continued focus on technological innovation R&D Expenditure Composition | Item | Current Period Amount (RMB) | | :--- | :--- | | Employee Compensation | 22,932,131.09 | | Amortization and Depreciation | 3,359,763.32 | | Material Consumption | 3,028,045.45 | | Technical Service Fees | 8,801,691.30 | | Experiment and Inspection Fees | 2,183,840.16 | | Other | 3,622,805.07 | | Total | 45,341,568.66 | | Of which: Expensed R&D Expenditures | 45,341,568.66 | - All R&D expenditures in the current period were expensed, with no R&D projects meeting capitalization criteria[644](index=644&type=chunk)[645](index=645&type=chunk) [9. Changes in Consolidation Scope](index=146&type=section&id=9.%20Changes%20in%20Consolidation%20Scope) The company's consolidation scope changed due to the liquidation and deregistration of Nanjing Xingong Medical Industry Investment Fund Partnership (Limited Partnership), which is no longer included in the consolidated financial statements - The company did not undergo business combinations not under common control during the reporting period[649](index=649&type=chunk) - The company did not undergo business combinations under common control during the reporting period[653](index=653&type=chunk) - Nanjing Xingong Medical Industry Investment Fund Partnership (Limited Partnership) has been liquidated and deregistered, and is no longer included in the company's consolidated financial statements[656](index=656&type=chunk) - There were no transactions or events resulting in the loss of control over subsidiaries in the current period[656](index=656&type=chunk) [10. Interests in Other Entities](index=149&type=section&id=10.%20Interests%20in%20Other%20Entities) The company holds interests in various controlled subsidiaries and associates, primarily in medical services and pharmaceutical production, with Nanjing Yitong Pharmaceutical Co., Ltd. having accumulated unrecognized excess losses Composition of the Enterprise Group (Partial Subsidiaries) | Subsidiary Name | Principal Place of Business | Nature of Business | Shareholding Proportion (Direct) | Acquisition Method | | :--- | :--- | :--- | :--- | :--- | | Nanjing Gulou Hospital Group Anqing Petrochemical Hospital Co., Ltd. | Anqing, Anhui | Medical Services | 87.77% | Business combination not under common control | | Yunnan Jinling Botanical Pharmaceutical Co., Ltd. | Pu'er, Yunnan | Production and Sales | 88.89% | Establishment | | Nanjing Gulou Hospital Group Suqian Hospital Co., Ltd. | Suqian, Jiangsu | Medical Services | 63.00% | Business combination not under common control | | Nanjing Meishan Hospital Co., Ltd. | Nanjing, Jiangsu | Medical Services | 51.00% | Business combination under common control | Significant Non-Wholly Owned Subsidiaries | Subsidiary Name | Minority Shareholding Proportion | Profit/Loss Attributable to Minority Shareholders in Current Period (RMB) | Dividends Declared and Distributed to Minority Shareholders in Current Period (RMB) | Period-End Minority Interest Balance (RMB) | | :--- | :--- | :--- | :--- | :--- | | Nanjing Gulou Hospital Group Suqian Hospital Co., Ltd. | 37.00% | 781,464.76 | 0 | 494,211,829.01 | | Nanjing Meishan Hospital Co., Ltd. | 49.00% | 1,595,042.66 | 7,840,000.00 | 411,419,905.43 | Significant Joint Ventures or Associates | Name of Joint Venture or Associate | Nature of Business | Shareholding Proportion (Direct) | Accounting Method | | :--- | :--- | :--- | :--- | | Nanjing Baijingyu Pharmaceutical Co., Ltd. | Production and Sales | 21.64% | Equity method accounting | | Nanjing Yitong Pharmaceutical Co., Ltd. | Goods Sales | 33.33% | Equity method accounting | - Nanjing Yitong Pharmaceutical Co., Ltd. has accumulated unrecognized prior-period losses of **RMB 6.35 million**, unrecognized losses of **RMB -3.07 million** in the current period, and accumulated unrecognized losses of **RMB 3.28 million** at period-end[678](index=678&type=chunk) [11. Government Grants](index=156&type=section&id=11.%20Government%20Grants) At period-end, the company recognized **RMB 0** in government grants receivable, with deferred income from asset-related grants at **RMB 0.84 million**, and **RMB 3.43 million** in grants recognized in current profit or loss - Government grants recognized as receivables at the end of the reporting period amounted to **RMB 0**[679](index=679&type=chunk) Liability Items Involving Government Grants | Liability Item | Beginning Balance (RMB) | Decrease in Current Period (RMB) | Period-End Balance (RMB) | Asset/Income Related | | :--- | :--- | :--- | :--- | :--- | | Deferred Income | 1,001,416.56 | 159,724.04 | 841,692.52 | Asset-related | Government Grants Recognized in Current Profit or Loss | Accounting Account | Current Period Amount (RMB) | | :--- | :--- | | Government grants directly recognized in profit or loss related to ordinary business activities | 2,631,674.90 | | Amortization of deferred income related to ordinary business activities | 159,724.04 | | VAT tax reductions and exemptions | 309,328.67 | | Total | 3,425,735.47 | [12. Risks Related to Financial Instruments](index=157&type=section&id=12.%20Risks%20Related%20to%20Financial%20Instruments) The company manages market, credit, and liquidity risks associated with financi

Group 1 - The company clarified that the trading financial assets of 1 billion are primarily structured deposits held with banks, and it only holds shares in Zijin Bank [2] - The cash balance of 1.3 billion represents the total amount held by the company and its subsidiaries, confirming that there has been no misappropriation of funds [2]

Group 1 - The core viewpoint of the article is that Jinling Pharmaceutical (000919) clarified its financial asset composition and liquidity status in response to investor inquiries [1] - The company holds 1 billion in trading financial assets, primarily in structured bank deposits, and only has shares in Zijin Bank [1] - The total cash balance reported is 1.3 billion, which includes funds held by the company and its subsidiaries [1]